Tonix Pharmaceuticals Holding Corp. (TNXP)

Interim Analysis Cancelled For Two Trials – Go Straight To Final Results


Robert LeBoyerMedia Inquiries
Senior Life Sciences Analyst
April 14, 2023
Report ID: 25748
Get Report
Refer to the full report for the price target, fundamental analysis, and rating.

Equity Research provided by Noble Capital Markets is available at no cost to Registered users of Channelchek.

Already Registered? Click the ‘Get Report’ button to login and view the research report.

Not a Member? Click ‘Join’ or ‘Get Report’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

Ticker
TNXP
Current Price
$0.374 -1.97%
Market Cap
$21.9M
Price Target
Refer to Report
Volume
918.6K
52wk Range
$0.26 - $6.6875
Related Research Reports
12/21/2023

Fibromyalgia Trial Meets All Endpoints
Fibromyalgia Trial Meets All Endpoints (TNXP)
9/6/2023

Long COVID Study Did Not Meet Primary Endpoint But Provides Important Data
Long COVID Study Did Not Meet Primary Endpoint But Provides Important Data (TNXP)
8/14/2023

Focus On CNS Transforms During 2Q23
Focus On CNS Transforms During 2Q23 (TNXP)
7/25/2023

New Tianeptine Data In Memory and Cognition Announced
New Tianeptine Data In Memory and Cognition Announced (TNXP)

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2024 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.